Preoperative prognostic value of alfa-fetoprotein density in patients with hepatocellular carcinoma undergoing radiofrequency ablation

References

• Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–1491.
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693.
   PubMed Web of Science ®Google Scholar
• Jacome AA, Castro ACG, Vasconcelos JPS, et al. Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: a Meta-analysis. JAMA Netw Open. 2021;4(12):e2136128.
   PubMed Web of Science ®Google Scholar
• European association for the study of the liver. Electronic address eee, European association for the study of the L. EASL clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68(2):723–750.
   PubMed Web of Science ®Google Scholar
• Abu-Hilal M, Primrose JN, Casaril A, et al. Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. J Gastrointest Surg. 2008;12(9):1521–1526.
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Kokudo N, Makuuchi M, et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol. 2013;58(4):724–729.
   PubMed Web of Science ®Google Scholar
• Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252(6):903–912.
   PubMed Web of Science ®Google Scholar
• Ross AE, Loeb S, Landis P, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol. 2010;28(17):2810–2816.
   PubMed Web of Science ®Google Scholar
• Loeb S, Bruinsma SM, Nicholson J, et al. Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol. 2015;67(4):619–626.
   PubMed Web of Science ®Google Scholar
• Konishi T, Shimada Y, Hsu M, et al. Association of preoperative and postoperative serum carcinoembryonic antigen and Colon cancer outcome. JAMA Oncol. 2018;4(3):309–315.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Imamura H, Matsuyama Y, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol. 2010;45(12):1272–1282.
   PubMed Web of Science ®Google Scholar
• Snyder RA, Hu CY, Cuddy A, Alliance for Clinical Trials in Oncology Network Cancer Surveillance Optimization Working Group, et al. Association between intensity of posttreatment surveillance testing and detection of recurrence in patients with colorectal cancer. JAMA. 2018;319(20):2104–2115.
   PubMed Web of Science ®Google Scholar
• Kim CG, Lee HW, Choi HJ, et al. Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. Cancer Med. 2019;8(11):5023–5032.
   PubMed Web of Science ®Google Scholar
• Kiriyama S, Uchiyama K, Ueno M, et al. Triple positive tumor markers for hepatocellular carcinoma are useful predictors of poor survival. Ann Surg. 2011;254(6):984–991.
   PubMed Web of Science ®Google Scholar
• Sfoungaristos S, Perimenis P. PSA density is superior than PSA and gleason score for adverse pathologic features prediction in patients with clinically localized prostate cancer. Can Urol Assoc J. 2012;6(1):46–50.
   PubMed Web of Science ®Google Scholar
• Deniffel D, Healy GM, Dong X, et al. Avoiding unnecessary biopsy: MRI-based risk models versus a PI-RADS and PSA density strategy for clinically significant prostate cancer. Radiology. 2021;300(2):369–379.
   PubMed Web of Science ®Google Scholar
• Huo YR, Glenn D, Liauw W, et al. Evaluation of carcinoembryonic antigen (CEA) density as a prognostic factor for percutaneous ablation of pulmonary colorectal metastases. Eur Radiol. 2017;27(1):128–137.
   PubMed Web of Science ®Google Scholar
• European association for the study of the L, European Organization for R, treatment of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Di Bisceglie AM, Bruix J, Panel of Experts in HCC-Design Clinical Trials, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698–711.
   PubMedGoogle Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259.
   PubMed Web of Science ®Google Scholar
• Kang TW, Kim JM, Rhim H, et al. Small hepatocellular carcinoma: radiofrequency ablation versus nonanatomic resection–propensity score analyses of long-term outcomes. Radiology. 2015;275(3):908–919.
   PubMed Web of Science ®Google Scholar
• Harrell F. Regression modelling strategies: with applications to linear models, logistic regression, and survival analysis. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. 2010.
   Google Scholar
• Bruix J, Sherman M, American Association for the Study of Liver Diseases American association for the study of liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022.
   PubMed Web of Science ®Google Scholar
• Chan SL, Mo FK, Johnson PJ, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol. 2009;27(3):446–452.
   PubMed Web of Science ®Google Scholar
• Shim JH, Han S, Lee YJ, et al. Half-life of serum alpha-fetoprotein: an early prognostic index of recurrence and survival after hepatic resection for hepatocellular carcinoma. Ann Surg. 2013;257(4):708–717.
   PubMed Web of Science ®Google Scholar
• Memon K, Kulik L, Lewandowski RJ, et al. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol. 2012;56(5):1112–1120.
   PubMed Web of Science ®Google Scholar
• Fujioka M, Nakashima Y, Nakashima O, et al. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology. 2001;34(6):1128–1134.
   PubMed Web of Science ®Google Scholar
• Gillespie JR, Uversky VN. Structure and function of alpha-fetoprotein: a biophysical overview. Biochim Biophys Acta. 2000;1480(1-2):41–56.
   PubMed Web of Science ®Google Scholar
• Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39(12):2214–2229.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Imamura H, Matsuyama Y, et al. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol. 2009;16(10):2795–2804.
   PubMed Web of Science ®Google Scholar
• Lee YK, Kim SU, Kim DY, et al. Prognostic value of alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer. 2013;13:5.
   PubMed Web of Science ®Google Scholar
• Montal R, Andreu-Oller C, Bassaganyas L, et al. Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. Br J Cancer. 2019;121(4):340–343.
   PubMed Web of Science ®Google Scholar
• Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of milan criteria. Gastroenterology. 2012;143(4):986–994.
   PubMed Web of Science ®Google Scholar
• Bai DS, Zhang C, Chen P, et al. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7(1):12870.
   PubMed Web of Science ®Google Scholar
• Toyoda H, Kumada T, Kaneoka Y, et al. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol. 2008;49(2):223–232.
   PubMed Web of Science ®Google Scholar
• Singal AG, Hoshida Y, Pinato DJ, et al. International liver cancer association (ILCA) white paper on biomarker development for hepatocellular carcinoma. Gastroenterology. 2021;160(7):2572–2584.
   PubMed Web of Science ®Google Scholar
• Cabibbo G, Maida M, Genco C, et al. Natural history of untreatable hepatocellular carcinoma: a retrospective cohort study. WJH. 2012;4(9):256–261.
   PubMedGoogle Scholar
• Hatzaras I, Bischof DA, Fahy B, et al. Treatment options and surveillance strategies after therapy for hepatocellular carcinoma. Ann Surg Oncol. 2014;21(3):758–766.
   PubMed Web of Science ®Google Scholar
• Bhangui P, Allard MA, Vibert E, et al. Salvage versus primary liver transplantation for early hepatocellular carcinoma: Do both strategies yield similar outcomes? Ann Surg. 2016;264(1):155–163.
   PubMed Web of Science ®Google Scholar
• Ma H, Zhang L, Tang B, et al. gamma-Glutamyltranspeptidase is a prognostic marker of survival and recurrence in radiofrequency-ablation treatment of hepatocellular carcinoma. Ann Surg Oncol. 2014;21(9):3084–3089.
   PubMed Web of Science ®Google Scholar
• Wu SJ, Lin YX, Ye H, et al. Prognostic value of alkaline phosphatase, gamma-glutamyl transpeptidase and lactate dehydrogenase in hepatocellular carcinoma patients treated with liver resection. Int J Surg. 2016;36(Pt A):143–151.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–558.
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Kaneko T, Saeed A, et al. Immunotherapy in hepatocellular cancer patients with mild to severe liver dysfunction: Adjunctive role of the ALBI grade. Cancers (Basel. 2020;12(7):1862.
   PubMed Web of Science ®Google Scholar
• Chen TM, Lin CC, Huang PT, et al. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol. 2012;27(3):553–561.
   PubMed Web of Science ®Google Scholar
• Zhang F, Lu SX, Hu KS, et al. Albumin-to-alkaline phosphatase ratio as a predictor of tumor recurrence and prognosis in patients with early-stage hepatocellular carcinoma undergoing radiofrequency ablation as initial therapy. Int J Hyperthermia. 2021;38(1):1–10.
   PubMed Web of Science ®Google Scholar
• Li S, Xu W, Liao M, et al. The significance of Gamma-Glutamyl transpeptidase to lymphocyte count ratio in the early postoperative recurrence monitoring and prognosis prediction of AFP-Negative hepatocellular carcinoma. JHC. 2021;ume 8:23–33.
   Web of Science ®Google Scholar